Endocrine Abstracts

Introduction: Liver involvement is frequent in Turner syndrome (TS) with a reported prevalence of abnormal liver function tests (LFTs) ranging 20–80%. Marked architectural changes and cirrhosis may be found in TS-women, associated with an increased incidence and risk of mortality.Recent studies and guidelines recommended:– monitoring annually all LFTs (International TS-Guidelines)– to improve d...

Introduction: Turner syndrome (TS) affects 1/1700 female, is due to total/partial lack of an X chromosome and besides short stature and gonadal dysgenesis, is associated with several comorbidities. No defined psychiatric condition has been related to TS. However, several case-reports have appeared in psychiatric literature, and TS is reported to be three times more prevalent in schizophrenia compared with the general female population.Aim: To evaluate th...

Background: Optimization of sex hormone replacement therapy (SHRT) is essential in long-term management of patients with hypogonadism. However, approaches to formulations of therapy, dose change (if any), monitoring of adequacy of therapy and safety are not standardised.Objectives: The survey aimed to establish the approach to management of SHRT for male and female hypogonadism.Methods: Online survey, live for 4 weeks (1/11/2021) d...

Introduction: The risk of maternal death from aortic-dissection(AoD) during pregnancy/post-partum in TS is increased, due to TS-associated risk factors (bicuspid-aortic-valve(BAV), aortic-coarctation, aortic-dilatation, hypertension) and the increased cardiovascular strain of pregnancy itself. TS-guidelines advice against pregnancy in the presence of severe aortic-dilatation or moderate dilatation with AoD-risk factors; and after aortic surgery a high risk remains. However, fe...

Introduction: Anaemia and other haematological disorders have been reported in Turner Syndrome (TS). TS-related comorbidities (premature ovarian insufficiency, autoimmune hypothyroidism, coeliac disease and liver diseases) and treatments (hormone replacement [HRT] and growth hormone) are possible explanations. We aim to investigate the prevalence of abnormal full blood count (FBC) in adult TS and assess associated clinical characteristics.Methods: FBC pa...

Generally, after an initial active phase TED rarely reactivates. However, epidemiological evidence is scant. The following cases highlight the propensity for Graves’ orbitopathy to reactivate many years later.Case 1: A 69-year-old woman had Graves’ disease aged 29, and was reviewed in the TED clinic (ophthalmology, rheumatology and endocrinology), with reactivation of orbitopathy 40 years after initial disease. She was an ex-smoker, had hyperte...

Introduction: Women with Turner syndrome (TS) have an increased risk of aortic dissection. Aortic dilatation, bicuspid aortic valve (BAV) and hypertension confer increased risk of dissection. However, only some women with these risk factors develop dissection, and others with no risk markers may dissect. Knowledge of the development of the aortopathy over time is limited. We investigate aortic dimension changes in unselected adult TS and associations between aortic growth and ...

Introduction: Elongated transverse aortic arch (ETA) has recently been described as the commonest abnormality (≅50%) in Turner syndrome (TS), exceeding the prevalence of bicuspid aortic valve (BAV; 10–30%) and aortic coarctation (CoA; 7–18%). Nevertheless only few studies focused on ETA. ETA was associated with BAV, CoA, 45,X and aortic dilatation.Aim: To evaluate the prevalence and associations of ETA in adult TS, unselected for cardiova...

Background: Thyroid eye disease (TED) is an autoimmune inflammatory disease associated with Graves’ disease. Rituximab (a monoclonal antibody that depletes B-cells), has recently been shown to be effective in treating TED. There is evidence to support an association with increased TRAbs and TED severity, and one study has demonstrated a fall in TRAbs with rituximab therapy. The aim of this study was to assess the clinical efficacy of low dose rituximab in patients with TE...

Background: Treatment of patients with acromegaly caused by pituitary adenoma with somatostatin analogues leads to significant tumour shrinkage in 23–73% of the cases. Although not widely accepted, it has been suggested that the surgical remission rate may be improved by pre-operative treatment with these agents.Aim: To assess whether the degree of tumour shrinkage by lanreotide offered pre-operatively affects the surgical success in acromegalics wi...